MedTrace Logo

Feasibility of Using NeoSpot at Community Settings

NCT05652777 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 149

Last updated 2025-03-12

No results posted yet for this study

Summary

Continuous vital sign monitoring is a basic tenet of specialized care in the developed world that is vastly underutilized during hospital or clinic admissions or outpatient routine visits in most low-and-middle income countries (LMICs). Despite the positive outcomes associated with vital sign monitoring (i.e., increased survival-to-discharge rates, lower complication rates and shorter length of stay in hospital), the prohibitive costs of conventional patient monitors and the difficulty in maintaining complex medical equipment limit its practice in the developing world.

Currently, due to lack of medical supplies, most ANC clinics - within the health facilities or during outreach activities - do not monitor for vital signs and blood pressure among pregnant women. While many devices exist, their ease of use and high-cost, including maintenance costs, hinder screening and monitoring programs in low resource settings. Accurate and low-cost vital sign monitoring devices are required to improve identification and treatment of women with danger signs during their routine ANC visits. To meet the growing demand for vital sign monitors during the COVID-19 pandemic, Neopenda has adapted an affordable, wearable, wireless vital sign monitoring solution (neoSpotTM), that measures temperature, respiration rate, blood oxygen saturation, pulse rate, and blood pressure.

Conditions

  • Pregnancy Related

Interventions

DEVICE

NeoSpot

Pregnant women will undergo screening of their vital signs using the NeoSpot device.

Sponsors & Collaborators

  • Neopenda, PBC

    collaborator INDUSTRY

  • Wellcome Trust

    collaborator OTHER

  • Centre for Infectious Disease Research in Zambia

    lead OTHER

Principal Investigators

  • Albert Manasyan, MD · Center for Infectious Disease Research in Zambia (CIDRZ)

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-01-15
Primary Completion
2024-04-30
Completion
2024-04-30

Countries

  • Zambia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05652777 on ClinicalTrials.gov